Transdermal treatment for pediatric HIV using a new drug formulation
Ionic liquid-based nanoemulsion containing combination antiretroviral drugs forthe transdermal treatment of pediatric HIV infection
['FUNDING_R21'] · UNIVERSITY OF ARIZONA · NIH-10923305
This study is looking at a new way to help kids with HIV by using a skin treatment instead of pills, making it easier for them to take their medicine and stick to their treatment plan.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ARIZONA (nih funded) |
| Locations | 1 site (TUCSON, UNITED STATES) |
| Trial ID | NIH-10923305 on ClinicalTrials.gov |
What this research studies
This research aims to develop a non-invasive transdermal treatment for pediatric patients with HIV, addressing the challenges of existing oral medications that are often difficult for children to take. By utilizing ionic liquid-based nanoemulsions, the study focuses on delivering combination antiretroviral drugs through the skin, which could improve adherence and make treatment more manageable for young patients. The approach seeks to create a stable formulation that can be self-administered, reducing the need for frequent oral dosing and overcoming barriers related to taste and pill burden. The research will explore the effectiveness of this method compared to traditional treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are pediatric patients aged 0-21 years who are living with HIV and face challenges with current treatment options.
Not a fit: Patients who are not living with HIV or those who are unable to use transdermal delivery methods may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment adherence and health outcomes for children living with HIV.
How similar studies have performed: While the transdermal delivery of antiretroviral drugs is a novel approach, preliminary studies have shown promise in using similar methods for other medications.
Where this research is happening
TUCSON, UNITED STATES
- UNIVERSITY OF ARIZONA — TUCSON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DATE, ABHIJIT A — UNIVERSITY OF ARIZONA
- Study coordinator: DATE, ABHIJIT A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus